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 Fucoxanthin is a carotenoid sourced and extracted mainly from dark orange and brown 
seaweeds found in the pacific ocean, such as the wakame algae. The allenic bonds and unique 
oxygen groups give fucoxanthin its unique structure and are thought to be part of the reason 
fucoxanthin has unique physiological functions. Fucoxanthin has potentially numerous effects on 
the physiology of human health, ranging from skin health to metabolic health, which have been 
demonstrated in animal model research. The goal of this review is to examine current literature 
to discuss fucoxanthin’s potential application as a nutraceutical, treatment for obesity, type 2 




Chapter 1: Introduction  
Fucoxanthin, a brown seaweed carotenoid, has the potential to be used to ameliorate a 
host of health issues, ranging from dermatitis1 and skin wrinkling 2 to prevention and treatment 
of several types of cancer in mouse models3–7. Fucoxanthin further provides benefits through 
unique mechanisms of action with regards to some of the world's most far-reaching diseases, 
such as obesity, diabetes, and other inflammatory diseases as shown in several murine model 
projects8–11. The unique actions of fucoxanthin may prove to be a beneficial additive treatment, 
or even as a stand-alone treatment option for those who prefer a holistic approach to health. 
  Fucoxanthin’s health benefits were first discussed in the late 1920s, as it was noted to be 
in high quantities in cod liver oil, a successful treatment for rickets12. In murine model research, 
the current literature now reveals fucoxanthin having benefits to health beyond treating rickets 
and directly benefitting diseases such as diabetes, heart disease, and obesity8–11. A small quantity 
of murine research emerged in the 2000s about fucoxanthin’s health benefits, however, most of 
the research on fucoxanthin is related to plant biology and physiology, leaving much to be 
explored in the field of human health and physiology. Many of the research projects examining 
the health benefits of fucoxanthin have been conducted in murine models, leaving a large gap in 
the literature on the potential benefits to humans. 
 The objective of this paper is to review the current body of literature relative to 
fucoxanthin’s potential benefits to human health and chronic disease management with specific 
regards to adiposity, blood glucose, inflammation, and blood lipids.   
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Chapter 2: Methods 
Three online databases (PubMed, Scopus, and Alt HealthWatch)  were reviewed using 
the following search terms: “fucoxanthin” combined with “diabetes”, “UCP1”, “Obesity”, 
“lipids”, and “inflammation”. Both animal and human research were included, as human 
experimental data on fucoxanthin is currently limited. Peer-reviewed articles reported in English 
from January 2000- March 2021 were included in the search review. All research included were 
full-text articles available through the James Madison University library databases at the time of 
authorship. (Figure 1) 
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Chapter 3: Manuscript 
History 
The earliest mention of fucoxanthin’s potential health benefits was in 1928 from Knut 
Wejdling, a Swedish researcher from Stockholm University. Wejdling was investigating the 
antirachitic nature of cod liver oil and found that fucoxanthin may act as a link for unsaturated 
carbon linkages found within cod liver. Wejdling hypothesized that during the depigmentation of 
fucoxanthin within the livers of deep water cod, lipids were released, yielding cod liver to 
become antiarachtic12.  
 The first true experimental trial showing fucoxanthin’s promising benefit to human health 
was published in 1990 from Jyunichi Okuzumi’s research group from the Kyoto Prefectural 
University of Medicine. Okuzumi’s group found that treating in-vitro human malignant tumor 
cells with a 10 μg/ml fucoxanthin serum for three days reduced the rate of growth of 
neuroblastoma cells to 38% of their original growth rates13. It was revealed that fucoxanthin 
inhibited the G0-G1 phases of the cell cycle, being the initial replicative steps of cell growth13. 
The same fucoxanthin serum reduced the expression of N-myc proto-oncogene protein, a gene 
that is responsible for cell proliferation in cancer cells13. Fucoxanthin was largely left unstudied 
in human trials following Okuzumi’s findings until the early 2000’s when research groups found 
anti-cancer effects in human prostate cells14,15, and inhibition of replicative DNA polymerase 
activity, lending fucoxanthin to being coined as an anti-neoplastic compound16. 
 Between these first mentionings of fucoxanthin in cod liver oil and its later application in 
its anti-cancer potential, most research about fucoxanthin was describing its general contribution 
to plant biology. James Mann and Jack Myers from The University of Texas, Austin, discussed 
the fact that fucoxanthin was much more efficient at energy transfer to chlorophyll during 
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photosynthesis than other carotenoids17. Fucoxanthin was also found to have significantly higher 
absorption rates of light across various spectrums (450-700nm) compared to other carotenoids 
commonly found in algae and referred to as Mann and Myers to be one of the most important  
light-absorbing pigments for the photosynthetic process17. 
Biological Properties 
 Contrasting with the majority of other carotenoids, fucoxanthin contains an allenic bond 
as well as the oxygen functional groups: beta-gamma-epoxy ketone, hydroxyl, carbonyl, and 
carboxyl groups18. Using ozonolysis to chemically degrade fucoxanthin, two synthetic 
fucoxanthin metabolites, apo-9’-fucoxanthinone, and apo-13-fucoxanthinone can be created19–21. 
Ozonolysis will chemically split the fucoxanthins polyene chain into two groups, one being a 
group with an allenic bond, and the other being a beta-gamma-epoxy ketone group21. Current 
literature would indicate that the two synthetic metabolites seemingly function the same as their 
organic counterparts22.  
In nature, carotenoids are absorbed by the Caco-2 cells in the intestinal lining, the same 
pathway as dietary fat due to the fact that all carotenoids are hydrophobic similar to lipids23. 
Fucoxanthin is metabolized into two different bioactive compounds, fucoxanthinol and 
amarouciaxanthin, with fucoxanthin primarily metabolizing into fucoxanthinol in the human 
gastrointestinal tract24. It has been suggested that lipase and carboxylesterase are released for the 
enzymatic breakdown of fucoxanthin in the gastrointestinal tract, and the hydrolyzed form of 
fucoxanthin is then absorbed by Caco-2 cells, then circulated by the lymphatic system23. The 
atypical functional oxygen groups are in part what gives fucoxanthin its molecular shape and 
unique biological function18,25. Among fucoxanthins numerous physiological functions, their 
effects on obesity, diabetes, inflammation, and dyslipidemia are extremely promising. It’s known 
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in the field of medicine and human health that obesity is associated with dyslipidemia, and will 
negatively impact inflammatory cytokines, which may cause type 2 diabetes26,27.   
Obesity 
The prevalence of obesity is far-reaching, showing prevalence in all races, sexes, and 
ages within the United States, and has become the most prevalent metabolic disease in the 
modern world28–32. Screening for obesity in a clinical setting can be done by calculating an 
individual’s body mass index (BMI) by using a person’s height and weight, with the highest risk 
group for developing chronic disease being those with a BMI greater than 29.9kg/m²33. While 
BMI may have limitations on describing body fatness for all individuals, it provides an effective 
estimation of body fatness for most patients within a clinical setting33,34. With rates of obesity in 
the United States being projected to continually increase30,35, alternative routes to help 
individuals manage their obesity, such as pharmacological aids and bariatric surgery amongst 
other plans, are constantly being developed and implemented36–38. Adipose tissue is comprised of 
two different subtypes of adipose, referred to as white adipose tissue (WAT) and brown adipose 
tissue (BAT). The main difference between WAT and BAT, with concerns to this review, is that 
BAT contains uncoupling protein-1 (UCP1)39. While UCP1 mRNA is found both within BAT, as 
well as WAT, but largely lay unexpressed, and dormant in most WAT cells, unless exposed to 
certain environmental factors such as extreme cold. UCP1 expression upregulating within WAT 
cells is reffered to as “browning”, as the tissue now displays the metabolic characteristics of 
BAT40 . UCP1 is found within the inner membrane of the mitochondria of BAT, and when UCP1 
is upregulated, protons outside of the mitochondrial space are taken by the UCP1 to produce heat 
(thermogenesis) rather than being utilized for energy41–45.  
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Murine rat models and limited human trials have revealed promising capabilities that 
fucoxanthin supplementation has the unique capability to induce UCP1 expression in WAT to 
stimulate whole-body adipose tissue loss10,11,18,46. A murine model study that was performed by 
Maeda et. al (2005) revealed that when KK-A(y) mice and Wister rats were fed either 0.32% or 
1.3% fucoxanthin by weight of diet for four weeks, UCP1 expression was almost 5 times higher 
in WAT when compared to the control group. WAT tissue relative to total body weight was over 
25% lower in the fucoxanthin-fed group, indicating the increased UCP1 expression within the 
WAT lead to overall weight loss 46. The fucoxanthin-fed mice and rats also had significantly 
lower body weight when compared to the control group, which can be solely attributed to the 
loss of WAT as there was no significant difference in the mean daily feeding intake, or other 
lifestyle factors between the fucoxanthin group and the control group46.  
In a study by Gille et. al,  researchers revealed that after 26 days, C57BL/6 mice gained 
less body fat when being fed a fucoxanthin-rich phaedoactylum triconutum extract (PTE) when 
compared to the placebo group. Gille et. al also found that the two groups of mice being fed 
either 2.4 mg/kg body weight or 7.1 mg/kg bodyweight of fucoxanthin had as high as 11x higher 
UCP1 expression compared to the placebo mice47. In the only human study of fucoxanthin’s 
effects on body fat, Abidov et. al found that when obese women supplemented with 2.4 mg of 
fucoxanthin for 16 weeks, they lost an average of 7.94 lb of body fat and had an average of a 
5cm decrease in waist circumference when compared to the placebo group48. While there is no 
current literature observing the expression of UCP1 in WAT of a human subject supplementing 
with fucoxanthin, the loss in body fat presented by Abidov et. al shows promise for the potential 
of UCP1 expression in WAT similar to those of Madea’s research in rats.  
Diabetes 
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Globally, type 2 diabetes mellitus (T2DM) has rapidly become one of the largest public 
health concerns49. T2DM is an extremely complex polygenic condition in which individuals have 
blunted insulin secretion or action (insensitivity), causing hyperglycemia and impaired 
carbohydrate metabolism50–52. Various medications, diets, exercise interventions, and even 
bariatric surgery have all been shown to be effective routes in treating T2DM53–58, with the most 
popular non-insulin-based drug being metformin59–64.   
Research conducted in murine models revealed that fucoxanthin may decrease blood 
glucose through a myriad of actions stemming from fucoxanthin’s ability to upregulate glucose 
transporter 4 (GLUT4) in muscle tissue8. Maeda et. al showed that after 4 weeks, out of the 24 
obese C57BL/6 mice, the groups that were fed a high-fat diet enriched with either 1.06%, or 
2.22% fucoxanthin, sourced from wakame lipids, had the same muscular GLUT4 activity, as 
well as plasma insulin and blood glucose levels as the non-obese mice8. Another murine model 
using C57BL/6 mice from Gille et. al, showed that after 26 days, the obese mice who received 
2.4 mg/kg body weight, or 7.1 mg/kg bodyweight of fucuxanthin had lower plasma insulin levels 
(27.7 mU/L and 33.5 mU/L, respectively) when compared to the placebo group (42.1 mU/L)47. 
Interestingly, the group that received the 2.4 mg/kg treatment had significantly lower 6 hour 
fasted plasma glucose (134 mg/dL) when compared to the group that was supplemented with 7.1 
mg/kg (179 mg/dL), who had plasma glucose levels higher than the placebo group (161 
mg/dL)47.  Through it’s utility in decreasing blood glucose using different pathways from 
pharmaceutical intervention, metformin, fucoxanthin may prove in the future to be a potential 
treatment option for those who cannot tolerate the GI discomfort from metformin, and may also 
serve as an additive prescriptive to an already metformin based intervention. 
Inflammation 
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Both chronic and acute inflammation is induced by the production of inflammatory 
cytokines in response to a stressor, and when left unchecked, chronically high-stress levels can 
lead to increased risk of non-communicable chronic disease development65,66. Interleukin-6 (IL-
6) is a cytokine heavily involved in acute and chronic inflammatory responses, as well as the 
regulation of various metabolic processes67–70. IL-6 has been demonstrated to play a critical role 
in the development and progression of pancreatic cancer tumor growth by stimulating cancerous 
neoplastic cells71. By blocking IL-6 activity via prescription Tocilizumab, researchers have been 
able to effectively treat the autoimmune disease rheumatoid arthirits72. Neutralizing IL-6 via IL-6 
antibodies has beneficial effects in other autoimmune diseases such as Castleman’s Disease, and 
juvenile idiopathic arthritis68.  
Tumor necrosis factor apha (TNF-α) is another inflammatory cytokine that is responsible 
for inducing cellular apoptosis, and activation of the proinflammatory nuclear factor-kB 
pathway(NF-kB)73. TNF-α directly impairs the signaling and responsiveness of insulin by 
upregulating serine phosphorylation on insulin receptor substrate 1 (IRS-1), leading to the 
development of insulin resistance74,75. 
Fucoxanthin has the ability to attenuate tumor necrosis factor-alpha (TNF-α), and leptin 
levels, both of which contribute to insulin resistance76,77. The same study previously mentioned 
in this section from Maeda et. al revealed that the C57BL/6 mice had more than 60% lower TNF-
α levels after being fed a high-fat diet enriched with fucoxanthin when compared to the control 
group, and the high-fat diet group who did not get the fucoxanthin8. Maeda et. al also showed 
that leptin mRNA levels expression was significantly lower in the groups being fed a high-fat 
diet, enriched with fucoxanthin when compared to the high-fat diet group that did not receive the 
fucoxanthin8. 
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Fucoxanthin supplementation has exhibited decreases in IL-6 and TNF-α in another 
murine model study from Jiang et. al using ICR mice. Seven days before treatment with a 
lipopolysaccharide injection, the group of ICR mice that were treated with 200 mg/kg of 
fucoxanthin had up to 55% lower concentration of  IL-6 and TNF-α in the hippocampus when 
compared to the group that received no fucoxanthin treatment. The same mice treated with 200 
mg/kg of fucoxanthin showed up to a 59% lower concentration of IL-6 and TNF-α in the frontal 
cortex, and up to a 51.9% lower concentration of IL-6 and TNF-α in the hypothalamus when 
compared to the group of mice that did not receive the fucoxanthin treatment78. The group of 
mice treated with 200 mg/kg of fucoxanthin also showed lower significantly lower expressions 
of NF-kB in the hippocampus, hypothalamus, and frontal cortex, indicating that one of the 
fucoxanthins potential routes of inflammation attenuation is by inhibiting the NF-kB pathway78. 
The mechanisms in how fucoxanthin inhibits the NF-kB pathway are currently still unclear79, but 
these preliminary studies provide the groundwork for future research to explore fucoxanthin’s 
mechanism(s) of action in inflammation. 
Hyperlipidemia 
Hyperlipidemia is a condition characterized by the elevation of serum triglycerides and/or 
low-density lipoprotein cholesterol (LDL-C) and is a strong risk factor for the development of 
cardiovascular disease (CVD)80–82. Hyperlipidemia impacts the function of vascular endothelial 
cells by damaging the vascular wall83. Pharmaceutical treatments such as statins work to reduce 
LDL-C84,85, by inhibiting endogenous cholesterol production. While statins are successful at 
attenuating hyperlipidemia, they are also associated with negative side effects such as 
myopathy86, development of T2DM87, and potential hemorrhagic strokes in those who have high 
blood pressure88,89. The supplementation of fucoxanthin may be a unique treatment for those 
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with hyperlipidemia that either prefer to not use statins, or who perhaps cannot tolerate statins as 
part of their treatment plan. 
In murine model experiments, fucoxanthin demonstrates promise as a potential treatment 
for hyperlipidemia, by having multiple effects on lipid profiles. Beppu et. al found that in obese 
KK-A(y) mice, that after 4 weeks of being on a diet containing 0.2% fucoxanthin increased 
serum serum high-density lipoprotein cholesterol (HDL-C) by 50 mg/dL, and reduced the 
amount of total cholesterol found in the liver by 4.6 mg90. Maeda et. al explored the effect of 
fucoxanthin in mice during a high-fat diet and found that after feeding C57BL/6 mice a high-fat 
diet, the groups receiving 1.06% and 2.22% fucoxanthin had up to 53% lower LDL-C when 
compared to the high-fat non-fucoxanthin group8. Research from Ha et. al has revealed that rats 
who were on a high-fat diet made up of 0.2% fucoxanthin for 4 weeks had 158% higher plasma 
HDL-C and 23% lower serum triglycerides, as well as 46% lower total liver cholesterol and 41% 
lower liver triglycerides, compared to the high-fat diet without fucoxanthin or a control diet 
groups91.  
These lipid-altering actions can be attributed to fucoxanthin downregulating the mRNA 
expression of SREBP-1c, a gene in which controls the lipogenic enzymes Acetyl-CoA 
carboxylase, fatty acid synthase, and glucose-6-phosphate dehydrogenase91. Fucoxanthin has 
also demonstrated the capability to upregulate CYP7A1 gene expression in the liver, causing 
more fecal excretion of cholesterol91. The aforementioned data collected insinuates that 
fucoxanthin supplementation, in addition to, or in replacement of a statin-based treatment 
regimen, may help decrease serum total cholesterol, LDL-C, and triglycerides, as well as 





In conclusion, fucoxanthin has the potential mechanisms to postivitley impact many 
different aspects of human health. Not only obesity, but glucose management, inflammation, and 
dyslipidemia may all be aided by fucoxanthin’s promising effects. Fucoxanthin has implications 
as a potential clinical intervention to help those who are overweight/obese, as these individuals 
can typically benefit from increased GLUT4 translocation, decreased adiposity, reduced 
inflammation, and lipid profile improvements. If fucoxanthin were to be used to attenuate any of 
the previously mentioned areas of health, there would be potential beneficial outcomes in other 
areas of health such as using fucoxanthin to reduce blood glucose, but also achieving a reduction 
in LDL-C for a patient with T2DM.  
The current landscape of literature is limited by numerous factors. As it stands, the 
majority of fucoxanthin-based research has been done in mouse model research. More research 
needs to be done in various human populations to examine fucoxanthin’s true effects on human 
health, as opposed to discussing its potential health effects for humans. In human studies, an 
established dose of fucoxanthin for supplementation should be investigated based on the desired 
health outcome. Hand in hand with an established dosage, researchers should elucidate any 
negative side effects, as well any interactions with other pharmaceutical or nutraceutical 
interventions, currently no human studies suggest harmful side effects. Long-term 
supplementation studies are another area of continued research that needs to be further 
established so that clinicians be aware of how long an individual can supplement with 
fucoxanthin. Further research is needed to elucidate more of fucoxanthin’s mechanisms of action 
that haven’t yet been discovered, such as exactly how fucoxanthin affects the expression of the 
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NF-kB pathway, as well as UCP1 genes, and the expression of mRNA signaling of Acetyl-CoA 
carboxylase, fatty acid synthase, and glucose-6-phosphate dehydrogenase via SREBP-1c. An 
investigation as to whether fucoxanthin will have a larger lipolytic effect on subcutaneous 
adipose tissue, or visceral adipose tissue may also prove to provide further insight into 
fucoxanthins use case. Fucoxanthin offers unique potential to be a nutraceutical treatment option 
for those who are obese, as fucoxanthin not only directly attenuates obesity, but also will 
attenuate the commonly associated co-morbidites of obesity, being T2DM, chronic 
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Table 1. In Vivo Fucoxanthin Research Effecting Obesity 
Title Author Subjects Treatment Results 
Anti-obesity and anti-diabetic effects of 
fucoxanthin on diet-induced obesity 







1.06% or 2.22% fucoxanthin by 
weight of diet 
 
Higher weight loss in FX 
groups, WAT gain was 
suppressed in FX group. Leptin 
mRNA expression up to 89% 
lower in the FX group.  
Dietary Combination of Fucoxanthin and 
Fish Oil Attenuates the Weight Gain of 
White dipose Tissue and Decreases Blood 







0.2% Fucoxanthin, or 0.1% 
Fucoxanthin + 6.9% Fishoil by 
weight of diet 
 
FX treated mice were 6.4g 
lighter on average compared to 
control group.  
 
Fucoxanthin from edible seaweed, Undaria 
pinnatifida, shows antiobesity effect 










1.3% or 0.3% Fucoxanthin by weight 
of diet for four weeks 
 
Over 25% lower WAT in Fx 
fed group. UCP1 expression 
~5x higher in WAT of subjects 
treated with Fx. 
 
A Lipophilic Fucoxanthin-
Rich Phaeodactylum tricornutum Extract 
Ameliorates Effects of Diet-Induced 







2.4mg fucoxanthin/kg bw or 7.1mg 
fucoxanthin kg/bw for 26 days 
 
Fx fed groups had UCP1 as 
high as 11x higher expression 
in inguinal WAT. 
 
The effects of Xanthigen™ in the weight 
management of obese premenopausal 
women with non-alcoholic fatty liver 









2.4mg fucoxanthin + 300mg 
pomegranate seed oil daily for 16 
weeks 
 
6.9kg +/1.9kg loss in body 
weight in the Fx group. 









Table 2. In Vivo Fucoxanthin Research Effecting Diabetes, Hyperlipidemia, and Inflammation 







diabetic effects of 
fucoxanthin on diet-
induced obesity 








1.06% or 2.22% 
fucoxanthin by weight of 
diet for 26 days 
 
Fx group regained 
healthy GLUT4 
levels in muscle 
tissue by the end 
of a high fat diet. 
 
  
Dietary Combination of 
Fucoxanthin and Fish 
Oil Attenuates the 
Weight Gain of White 











0.2% Fucoxanthin, or 
0.1% Fucoxanthin + 6.9% 




insulin in FX fed 
groups. 
53% lower LDL-














0.2% Fucoxanthin by 
weight of diet for 4 weeks 
 
 
Serum HDL 50 
mg/dL higher, 
and 4.6g less liver 







Ameliorates Effects of 
Diet-Induced Obesity 







2.4mg fucoxanthin/kg bw 
or 7.1mg fucoxanthin 
kg/bw for 26 days 
 
Fx treated mice 






The effect of 
fucoxanthin rich power 
on the lipid metabolism 










4% Fucoxanthin by 





46% lower liver 
cholesterol, and 
41% lower liver 
triglycerides in 



































of Fx group had 
55%, 59%, and 
51.9% lower IL-6 
and TNF-α in the 
hippocampus, 




Fx group also had 
lower NF-kB 
expression 
compared to 
control. 
 
 
